^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rui Bi Da (rezivertinib) (EGFR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Central nervous system efficacy of Rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: a pooled analysis of two clinical studies
Published date:
04/16/2023
Excerpt:
Rezivertinib demonstrated encouraging clinical CNS efficacy among advanced NSCLC patients with EGFR T790M mutation and CNS metastases.
DOI:
https://doi.org/10.1016/j.lungcan.2023.107194
Trial ID:
Source:
Title:
Efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M mutated NSCLC: a phase IIb study
Published date:
08/29/2022
Excerpt:
The ORR by BICR was 64.6% (95%CI: 58.0%-70.8%) and DCR was 89.8% (95%CI: 85.1%-93.4%). The median DoR was 12.5 months (95%CI: 10.0-13.9) and median PFS was 12.2 months (95%CI: 9.6-13.9). The median OS was 23.9 months (95%CI: 20.0-NC)….Rezivertinib demonstrated promising efficacy and favorable safety profile for locally advanced or metastatic/recurrent NSCLC patients with EGFR T790M mutation.
DOI:
10.1016/j.jtho.2022.08.015
Trial ID:
Source:
Title:
Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: A phase IIb, multicenter, single-arm, open-label study.
Published date:
05/26/2022
Excerpt:
By the data cutoff date on Dec 23, 2021, the ORR by BICR was 64.6% (95%CI:58.0-70.8) and DCR was 89.8% (95%CI:85.1-93.4). The median DoR was 12.5 (95%CI:10.0-13.9) months and median PFS was 12.2 (95%CI:9.6-13.9) months….Rezivertinib demonstrated promising efficacy and favorable safety for locally advanced or metastatic/recurrent NSCLC patients with EGFR T790M mutation.
DOI:
10.1200/JCO.2022.40.16_suppl.9098
Trial ID:
Source:
Title:
Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study
Published date:
02/18/2022
Excerpt:
The overall BICR-assessed ORR was 59.3% (102/172, 95% confidence interval [CI]: 51.6, 66.7), and the median progression-free survival was 9.7 (95% CI: 8.3, 11.1) months.Rezivertinib showed promising efficacy with a manageable safety profile in patients with EGFR T790M-mutated advanced NSCLC.
DOI:
10.1016/j.jtho.2022.01.015
Trial ID:
